13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001969764
Total reported value
$191.1M
$191.1M
21 檔
33.0%
During the Q4 2024 filing period, Propel Bio Management, LLC (CIK: 0001969764) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $191.1M across 21 reported positions.
During Q4 2024, Propel Bio Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PAGP | Plains Gp Holdings Lp-cl A | Stock-Energy | 23.23% | -2.86% | — | |
| 2 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 13.19% | — | — | |
| 3 | AKRO | Akero Therapeutics Inc | Stock-Other | 9.50% | — | — | |
| 4 | ACHV | Achieve Life Sciences Inc | Stock-Other | 8.58% | +6.62% | — | |
| 5 | APLT | Applied Therapeutics Inc | Stock-Other | 8.18% | — | +46.40% | |
| 6 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 7.98% | +0.06% | +13.79% | |
| 7 | TCRX | Tscan Therapeutics Inc | Stock-Other | 6.30% | — | — | |
| 8 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 5.16% | — | — | |
| 9 | ARDX | Ardelyx Inc | Stock-Other | 4.79% | — | -11.21% | |
| 10 | ABEO | Abeona Therapeutics Inc | Stock-Other | 3.45% | -0.61% | — | |
| 11 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.41% | — | +37.52% | |
| 12 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.25% | — | — | |
| 13 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 1.49% | +0.24% | — | |
| 14 | KURA | Kura Oncology Inc | Stock-Other | 1.12% | — | — | |
| 15 | ✓ | Athira Pharma Inc | Stock-Other | 0.87% | — | — | |
| 16 | 72C | Eiger Biopharmaceuticals Inc | Stock-Other | 0.76% | — | — | |
| 17 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.42% | — | — | |
| 18 | DCTH | Delcath Systems Inc | Stock-Other | 0.20% | -0.03% | — | |
| 19 | CMPS | Compass Pathways PLC | Stock-Other | 0.09% | +1.64% | -68.49% | |
| 20 | ✓ | Maat Pharma Saca | Stock-Other | 0.02% | — | +31.46% | |
| 21 | ✓ | Chinook Therapeutics Cvr | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Propel Bio Management, LLC reported a total U.S. public equity portfolio value of $191.1M across 21 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PAGP, MDGL, AKRO) accounted for 33.0% of total reported equity market value during Q4 2024.
During Q4 2024, Propel Bio Management, LLC's top holdings by market value included PAGP (23.2%)、MDGL (13.2%)、AKRO (9.5%). The largest single position, PAGP, represented 23.2% of total portfolio value.
In Q4 2024, Propel Bio Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.